ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 431,04
-0,79%
Dow Jones
41 938,45
-1,63%
DAX
20 214,79
-0,51%
Brent Oil
79,285
0,00%
Bitcoin
95 186,04
0,65%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. uniQure NV (QURE)

  7. uniQure NV (QURE) Actualités

QURE

uniQure NV (QURE)

uniQure NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:QURE
DateHeureSourceTitreSymboleSociété
08/01/202522h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
08/01/202522h21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:QUREuniQure NV
08/01/202513h05GlobeNewswire Inc.uniQure Announces Pricing of its Public OfferingNASDAQ:QUREuniQure NV
07/01/202522h49GlobeNewswire Inc.uniQure Announces Proposed Public OfferingNASDAQ:QUREuniQure NV
07/01/202522h42Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:QUREuniQure NV
10/12/202422h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
10/12/202422h33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:QUREuniQure NV
10/12/202413h05GlobeNewswire Inc.uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s DiseaseNASDAQ:QUREuniQure NV
21/11/202413h05GlobeNewswire Inc.uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe EpilepsyNASDAQ:QUREuniQure NV
14/11/202418h01Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:QUREuniQure NV
05/11/202415h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
05/11/202413h05GlobeNewswire Inc.uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
15/10/202413h05GlobeNewswire Inc.uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALSNASDAQ:QUREuniQure NV
23/09/202413h05GlobeNewswire Inc.uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry DiseaseNASDAQ:QUREuniQure NV
15/08/202413h05GlobeNewswire Inc.uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseNASDAQ:QUREuniQure NV
01/08/202414h54Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:QUREuniQure NV
01/08/202413h05GlobeNewswire Inc.uniQure Announces Second Quarter 2024 Financial Results and Provides Company UpdateNASDAQ:QUREuniQure NV
23/07/202413h05GlobeNewswire Inc.uniQure Announces Closing of Sale of Manufacturing Facility to GenezenNASDAQ:QUREuniQure NV
09/07/202413h05GlobeNewswire Inc.uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s DiseaseNASDAQ:QUREuniQure NV
01/07/202413h05GlobeNewswire Inc.uniQure Announces Sale of Commercial Manufacturing Facility to GenezenNASDAQ:QUREuniQure NV
01/07/202413h05PR Newswire (US)Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MANASDAQ:QUREuniQure NV
03/06/202413h05GlobeNewswire Inc.uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s DiseaseNASDAQ:QUREuniQure NV
07/05/202413h05GlobeNewswire Inc.uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
28/02/202413h05GlobeNewswire Inc.uniQure Announces 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
13/02/202422h33Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:QUREuniQure NV
19/12/202313h05GlobeNewswire Inc.uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseaseNASDAQ:QUREuniQure NV
12/12/202301h30PR Newswire (US)CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia BNASDAQ:QUREuniQure NV
08/12/202313h05GlobeNewswire Inc.uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:QUREuniQure NV
29/11/202313h05GlobeNewswire Inc.uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry DiseaseNASDAQ:QUREuniQure NV
07/11/202313h05GlobeNewswire Inc.uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
 Showing the most relevant articles for your search:NASDAQ:QURE

Dernières Valeurs Consultées

LSE
QH00
Morg.st.b.v 26
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés